ELOVL6
Reactivité: Humain
WB, IF (cc), IF (p)
Hôte: Lapin
Polyclonal
AbBy Fluor® 750
Indications d'application
ELISA. Western blot: 1 - 2 μg/mL. Immunohistochemistry. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Buffer
PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
anticorps FACE, anticorps FAE, anticorps LCE, anticorps C77826, anticorps Lce2, anticorps rELO2, anticorps lce, anticorps cb618, anticorps zgc:73089, anticorps elovl6, anticorps ELOVL fatty acid elongase 6, anticorps ELOVL family member 6, elongation of long chain fatty acids (yeast), anticorps elongation of very long chain fatty acids protein 6, anticorps elongation of very long chain fatty acids protein 6-like, anticorps ELOVL6, anticorps Elovl6, anticorps elovl6, anticorps Tsp_06132, anticorps LOC108710167
Sujet
Lipogenesis is a key event in the energy storage system and is controlled by the transcription factor sterol regulatory element-binding protein (SREBP)-1. Elongation of very long chain fatty acids protein 6 (ELOVL6) is a member of fatty acyl-CoA elongase gene family that converts palmitic to stearic acid and it has been shown to be a target of SREBP-1, playing an important role in de novo synthesis of long-chain saturated and monosaturated fatty acids in conjunction with fatty acid synthase and stearoyl-CoA desaturase ELOVL6 was predicted to be important for tissue fatty acid composition. Recent studies suggest that inhibition of this elongase could be a new therapeutic approach for ameliorating insulin resistance, diabetes and cardiovascular risks, even in the presence of a continuing state of obesity.Synonyms: Elongation of very long chain fatty acids protein 6, FACE, Fatty acyl-CoA elongase, LCE, Long-chain fatty-acyl elongase, hELO2